The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) ##STR00001## wherein R.sup.1 to R.sup.9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.